<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11680080</article-id><article-id pub-id-type="doi">10.3390/vaccines12121452</article-id><article-id pub-id-type="publisher-id">vaccines-12-01452</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Measles Among the Foreign-Born Population Residing in Spain, 2014&#x02013;2022: Missed Opportunities for Vaccination</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5132-314X</contrib-id><name><surname>L&#x000f3;pez-Perea</surname><given-names>Noem&#x000ed;</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-vaccines-12-01452" ref-type="aff">1</xref><xref rid="af2-vaccines-12-01452" ref-type="aff">2</xref><xref rid="af3-vaccines-12-01452" ref-type="aff">3</xref><xref rid="c1-vaccines-12-01452" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5542-9782</contrib-id><name><surname>L&#x000f3;pez-Cuadrado</surname><given-names>Teresa</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af1-vaccines-12-01452" ref-type="aff">1</xref><xref rid="af3-vaccines-12-01452" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7504-5321</contrib-id><name><surname>Fern&#x000e1;ndez-Garc&#x000ed;a</surname><given-names>Aurora</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af2-vaccines-12-01452" ref-type="aff">2</xref><xref rid="af4-vaccines-12-01452" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7522-850X</contrib-id><name><surname>Echevarr&#x000ed;a</surname><given-names>Juan E.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af2-vaccines-12-01452" ref-type="aff">2</xref><xref rid="af4-vaccines-12-01452" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2725-417X</contrib-id><name><surname>Masa-Calles</surname><given-names>Josefa</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-vaccines-12-01452" ref-type="aff">1</xref><xref rid="af2-vaccines-12-01452" ref-type="aff">2</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Adekanmbi</surname><given-names>Victor</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-12-01452"><label>1</label>National Centre for Epidemiology, Institute of Health Carlos III, 28029 Madrid, Spain</aff><aff id="af2-vaccines-12-01452"><label>2</label>Spanish Consortium for Research in Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain</aff><aff id="af3-vaccines-12-01452"><label>3</label>Department of Preventive Medicine and Public Health, School of Medicine, Autonomous University of Madrid, 28029 Madrid, Spain</aff><aff id="af4-vaccines-12-01452"><label>4</label>National Centre for Microbiology, Institute of Health Carlos III, 28220 Madrid, Spain</aff><author-notes><corresp id="c1-vaccines-12-01452"><label>*</label>Correspondence: <email>nlopezp@isciii.es</email></corresp></author-notes><pub-date pub-type="epub"><day>23</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>12</volume><issue>12</issue><elocation-id>1452</elocation-id><history><date date-type="received"><day>15</day><month>11</month><year>2024</year></date><date date-type="rev-recd"><day>17</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>21</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Background/Objectives: Spain has been in a measles elimination phase since 2014. No evidence exists about the distribution of measles cases among the population born outside Spain. The aim of this study was thus to describe the epidemiological situation of measles, stratified by place of birth, during the post-elimination period in Spain. Methods: This is a retrospective study of confirmed measles cases reported to RENAVE between 2014 and 2022. A descriptive analysis of case characteristics (sex, age group, vaccination status, imported case) was performed, was well as an analysis of temporal trends and geographic distribution in measles incidence rate (IR; cases/million inhabitants). All analyses were stratified by place of origin (Spain born vs. born outside Spain). We then performed a sensitivity analysis of those born outside Spain, with the representation of Kaplan&#x02013;Meier curves taking into account the year of arrival in the country until the onset of measles. Results: Between 2014 and 2022, 951 measles cases were reported in Spain (overall IR: 2.3). Among these, 18.6% (177 cases, IR: 3.0) were born outside Spain. The IRs show differences (<italic toggle="yes">p</italic> &#x0003c; 0.001) in terms of distribution by age group and origin. By age group, children under 5 years had the highest IR, but adults aged 30 years and older reported the highest proportion of cases. The incidence rate ratio (IRR) was 5-fold higher among foreign-born children under 5 years than among native-born children. The measles time trend shows the highest peak in 2019 for foreign-born and native-born (IR: 8.6 and 5.4, respectively), consistent with the European-wide scenario, while only one case of measles was reported in 2022. Geographical variability in incidence rates by region was observed: Catalonia and the Valencian Community accumulated the highest proportion of cases throughout the study period. Among those born outside Spain, the median time from arrival to onset of rash was 6 years. Conclusions: The incidence of measles is 40% higher in Spain&#x02019;s foreign-born population than in its native-born population. Taking into account the increasing migrant population in Spain, we consider that public health efforts need to be directed towards susceptible groups of people. In this context of advanced elimination, specific interventions for identifying and attending the most vulnerable populations should be designed and implemented.</p></abstract><kwd-group><kwd>measles</kwd><kwd>elimination</kwd><kwd>migrants</kwd><kwd>Spain</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-12-01452"><title>1. Introduction</title><p>Its high contagiousness and potential associated complications make measles a disease with one of the highest morbidity and mortality burdens. Despite there being a safe and effective vaccine, measles remains a challenge for health systems and the health of populations.</p><p>In 1988, the World Health Assembly proposed a 90% reduction in measles cases and 95% of associated deaths [<xref rid="B1-vaccines-12-01452" ref-type="bibr">1</xref>] by 2000. Progress in measles elimination differs across World Health Organization (WHO) regions, determined in all cases by the integrity of populations&#x02019; immunity to measles. The region of the Americas was the first to reach the goal of measles elimination in 2002 [<xref rid="B2-vaccines-12-01452" ref-type="bibr">2</xref>,<xref rid="B3-vaccines-12-01452" ref-type="bibr">3</xref>].</p><p>In 1999, at the request of WHO-Europe, the European Advisory Group on Immunization published the Strategic Framework for Measles Elimination in the European Region [<xref rid="B4-vaccines-12-01452" ref-type="bibr">4</xref>,<xref rid="B5-vaccines-12-01452" ref-type="bibr">5</xref>] The strategic lines for the goal of elimination are to maintain high vaccine coverage (&#x02265;95% with two doses of measles, mumps and rubella vaccine (MMR)), increase vaccination opportunities for potentially susceptible populations and groups, improve epidemiologic surveillance and laboratory investigation of cases and outbreaks, and ensure rapid control of outbreaks. A further recommendation is to improve the capability of healthcare workers to inform the public about the benefits/risks of measles vaccination, with the aim of strengthening demand and improving confidence in vaccination.</p><p>In 2019, measles challenged global health systems because of its alarming resurgence. Only the COVID-19 pandemic radically halted that upward trend. In 2022, however, about 136,000 people died of measles worldwide, 43% more than in 2021, most of whom were under the age of 5 years and living in developing countries [<xref rid="B6-vaccines-12-01452" ref-type="bibr">6</xref>]. At the beginning of 2024, the European Center for Disease Prevention and Control published a report with a threat assessment of the rapid increase in the reporting of measles cases and outbreaks in 2023 in the European Union/European Economic Area [<xref rid="B7-vaccines-12-01452" ref-type="bibr">7</xref>].</p><p>Spain, having achieved 95% coverage with one MMR dose and incidence of less than one case per 100,000 inhabitants, added its name to the list of countries that reached the goal of measles elimination by 2000 [<xref rid="B8-vaccines-12-01452" ref-type="bibr">8</xref>]. In 2021, the Strategic Plan for Measles and Rubella Elimination in Spain 2021&#x02013;2025 was updated, adapting to the epidemiological reality and including the new laboratory algorithms proposed by the WHO [<xref rid="B9-vaccines-12-01452" ref-type="bibr">9</xref>].</p><p>The coverage with two doses of MMR in the European Region was 91% in 2023 (95% with one dose) [<xref rid="B7-vaccines-12-01452" ref-type="bibr">7</xref>]. However, there are significant differences among countries within the region [<xref rid="B10-vaccines-12-01452" ref-type="bibr">10</xref>].</p><p>The report of the last meeting of the Commission for Verification of the Elimination of Measles and Rubella in the European Region, based on data for 2022, concluded that the situation was heterogeneous. Of the 53 countries in the region, measles elimination status could be certified in 33; and while the disease remained endemic in 9 countries, including Romania, Ukraine and Poland, endemic transmission had only been halted in others, such as France, Italy and Germany, in the previous 12 months [<xref rid="B11-vaccines-12-01452" ref-type="bibr">11</xref>]. In Europe, there are countries in the elimination phase that have traditionally been immigration hosts, like the United Kingdom or Sweden. Pockets of susceptible people, such as adult immigrants who are often not offered vaccination on arrival [<xref rid="B12-vaccines-12-01452" ref-type="bibr">12</xref>] could pose a challenge to measles control. For this case, RCV recommended supplementary immunization activity (SIA) campaigns for improving vaccination coverages. Measles elimination status is not final, so that if circulation renews, as in Uzbekistan, measles circulation status can be reinstated.</p><p>In Spain, MMR was included in the childhood vaccination schedule in 1981, and the second dose was incorporated in 1996. The current MMR schedule envisages administration at age 12 months and again at 3&#x02013;4 years. In 2019, there was an essential shift from the Child Vaccination Calendar to the Lifelong Vaccination Calendar, in which vaccination with two doses of MMR is recommended for every person born in Spain since 1978 without documented vaccination, by taking advantage of any contact with health services [<xref rid="B13-vaccines-12-01452" ref-type="bibr">13</xref>].</p><p>The fact that there has been no endemic circulation of measles in this country since 2014, the so-called post-elimination phase, meant that the WHO European Regional Verification Committee was able to certify the measles elimination status in Spain in 2017. This post-elimination period is characterized by imported cases of measles coming from other countries where the virus is still circulating, and where there are outbreaks; these are usually small or medium-sized [<xref rid="B14-vaccines-12-01452" ref-type="bibr">14</xref>].</p><p>The migrant population resident in Spain comes from countries where different vaccination policies have been implemented, and this determines the likelihood of a person being immune or susceptible to measles: whereas younger people may have benefited from the scheduled inclusion of MMR, older people may have gone through measles naturally.</p><p>The WHO noted that migrant populations may experience more difficulties in accessing health systems and receiving vaccination than populations born in the countries of arrival [<xref rid="B15-vaccines-12-01452" ref-type="bibr">15</xref>]. In response to this need, it therefore, published a Global Action Plan for Health Promotion among Migrants and Refugees [<xref rid="B16-vaccines-12-01452" ref-type="bibr">16</xref>], which has been extended until 2030 [<xref rid="B17-vaccines-12-01452" ref-type="bibr">17</xref>].</p><p>There is no scientific evidence at a national level on the distribution and characteristics of measles cases among the population born outside Spain. The aim of this study was thus to describe the epidemiological situation (temporal and geographical) of measles, stratified by place of birth, during the post-elimination period in Spain.</p></sec><sec id="sec2-vaccines-12-01452"><title>2. Materials and Methods</title><p>We conducted a retrospective study of confirmed cases of measles (by laboratory, epidemiological link clinical diagnosis) reported to Spain&#x02019;s National Epidemiological Surveillance Network (Red Nacional de Vigilancia Epidemiol&#x000f3;gica/RENAVE) across the period 2014&#x02013;2022. The RENAVE is an essential system for the detection and control of communicable diseases and other health risks, enabling a rapid and coordinated response at a national level [<xref rid="B18-vaccines-12-01452" ref-type="bibr">18</xref>]. Measles is a notifiable disease in Spain and its enhanced surveillance is one of the cornerstones for maintaining post-elimination status, as outlined in the Measles Elimination Strategic Plan [<xref rid="B9-vaccines-12-01452" ref-type="bibr">9</xref>]. This ensures the completeness and quality of data for each suspected measles case entering the system.</p><p>The population figures published by the National Statistics Institute (Instituto Nacional de Estad&#x000ed;stica/INE) on 1 January of each year of study [<xref rid="B19-vaccines-12-01452" ref-type="bibr">19</xref>] were used for the calculation of rates.</p><p>We performed a descriptive analysis of the sociodemographic, risk characteristics and place of acquisition of infection of cases by the following factors: sex; age group (under 5 years, 5 through 29 years, and 30 years and older); Autonomous Region (Comunidad Aut&#x000f3;noma) of notification; imported case (yes/no); place of origin (born in Spain vs. born abroad); and vaccination status (yes/no), with &#x02018;vaccinated person&#x02019; being defined as anyone who had received at least one MMR dose.</p><p>In the case of those born outside Spain, the continent and main countries of origin were described. The association between place of origin and the mentioned qualitative covariates was explored using Pearson&#x02019;s chi-squared test. Measles incidence rates (cases/million population) were calculated by age group and year, along with the incidence rate ratio and its corresponding confidence interval (IRR, 95% CI).</p><p>Time trends in measles incidence rates and the geographical distribution of rates and proportions were plotted. A sensitivity analysis was performed for the migrant population group, using Kaplan&#x02013;Meier curves, with follow-up time being defined as time (in years) from arrival in the country to the onset of measles, indicating the median time.</p><p>We performed the analysis using Stata<sup>&#x000a9;</sup> v17 (StataCorp. 2021. Stata Statistical Software: Release 17. College Station, TX, USA: StataCorp LLC.)</p><p>All results were reported by place of origin (born in Spain vs. born abroad), excluding all cases of measles among the migrant population not residing in Spain (40 cases (4.0%)).</p></sec><sec sec-type="results" id="sec3-vaccines-12-01452"><title>3. Results</title><p>From 2014 through 2022, 951 cases of measles were reported among the population living in Spain; of these, 18.6% (177) had been born outside Spain. Depending on their place of origin, differences were found between cases with known vaccination status (91.8%), with the unvaccinated proportion being higher among residents born outside Spain than among Spanish natives (67.3% vs. 62.8%). A similar situation was observed in the proportion of imported cases (23.6% vs. 6.2%) (<xref rid="vaccines-12-01452-t001" ref-type="table">Table 1</xref>).</p><p>The overall measles incidence rate across the study period was 2.3 cases per million population, with incidence being higher among those born outside than among those born in Spain (incidence rate (IR): 3.0 vs. 2.1; IRR = 1.4 (95% CI: 1.2&#x02013;1.6)).</p><p>By age group, the highest proportion of cases was reported among adults aged 30 years and over (49.7%), and the highest incidence occurred among children under 5 years of age (IR: 9.1 cases/million). After stratification by place of origin, rates in children under 5 years of age were significantly higher among those born abroad than among those born in Spain (IR: 42.3 vs. 8.2; IRR: 5.1; 95% CI (3.0&#x02013;8.3)) (<xref rid="vaccines-12-01452-t002" ref-type="table">Table 2</xref>). In the 5&#x02013;29 age group, rates were likewise significantly higher among residents born in other countries (IR: 5.4 vs. 2.4; IRR: 2.2; 95% CI: (1.7&#x02013;2.9)), whereas in the 30-and-over age range, the IRRs were similar between the two groups (<xref rid="vaccines-12-01452-t002" ref-type="table">Table 2</xref>).</p><p>The measles time trend shows the highest peak in 2019 for both groups (IR: 8.6 and 5.4, respectively), while only one case of measles was reported in 2022 (<xref rid="vaccines-12-01452-f001" ref-type="fig">Figure 1</xref>).</p><p>Of the 177 cases reporting a foreign origin, 55.9% came from European countries, with Romania (32 cases), Italy (23 cases) and Ukraine (18 cases) being the most frequent countries of origin. The next most frequently sourced continents were the Americas (24.3%), Africa (6.2%) and Asia (2.3%) (<xref rid="vaccines-12-01452-f002" ref-type="fig">Figure 2</xref>).</p><p>Among those born outside Spain, the median time from arrival to onset of rash was 6 years. A breakdown by age group showed that the median time was 1 year, 4 years and 8 years for those aged under 5 years, 5&#x02013;29 years, and &#x02265;30 years, respectively (<xref rid="vaccines-12-01452-f003" ref-type="fig">Figure 3</xref>).</p><p>Wide geographic variability was observed in measles reporting by Autonomous Region. The regions with the most cases of measles were Catalonia (43.2%) and Valencia (19.6%), accounting for 63% of all notifications across Spain, followed by Madrid (8.1%), Castile-La Mancha (7.3%), and Andalusia (5.6%) (<xref rid="app1-vaccines-12-01452" ref-type="app">Table S1</xref>). The percentage of cases of foreign origin in a given region varied from 30.2% in Andalusia to 10.1% in Castile-La Mancha, with Catalonia and Valencia registering the highest incidences among the population of foreign origin (IR: 6.3 and 4.2, respectively) (<xref rid="app1-vaccines-12-01452" ref-type="app">Table S1</xref> and <xref rid="app1-vaccines-12-01452" ref-type="app">Figure S1</xref>).</p></sec><sec sec-type="discussion" id="sec4-vaccines-12-01452"><title>4. Discussion</title><p>In the post-elimination phase in Spain, with endemic transmission of the measles virus interrupted, the risk of an imported case generating an outbreak depends on the susceptibility of the population group to which it belongs, and/or the area in which the imported case arrives. This rate of susceptibility may depend on, among other things, vaccination policies and coverage in the countries where people come from.</p><p>The years prior to the COVID-19 pandemic (2018&#x02013;2019) saw an alarming resurgence of measles cases and outbreaks in all WHO regions, due to uneven or sub-optimal vaccination coverage (&#x0003c;95% with two doses of MMR) [<xref rid="B3-vaccines-12-01452" ref-type="bibr">3</xref>,<xref rid="B20-vaccines-12-01452" ref-type="bibr">20</xref>].</p><p>Following the sharp global drop in measles reporting due to pandemic barriers, lockdown, and distancing measures (2020 and 2021), there has been a new resurgence of the disease in the last two years [<xref rid="B6-vaccines-12-01452" ref-type="bibr">6</xref>,<xref rid="B21-vaccines-12-01452" ref-type="bibr">21</xref>]. The pandemic also had an impact on health systems in terms of the performance of immunization programs, as in the case of the European Region, where MMR coverage decreased from 2020 through 2022 (falling from 96% to 93% with one MMR dose between 2019 and 2022, and from 92% to 91% with two doses) [<xref rid="B3-vaccines-12-01452" ref-type="bibr">3</xref>,<xref rid="B22-vaccines-12-01452" ref-type="bibr">22</xref>]. This, coupled with the recovery of the international movement of people, resulted in more than 60,000 cases of measles and 13 related deaths being reported in the region in 2023, and the scenario has become even worse in 2024, with more than 95,000 cases having been reported to date [<xref rid="B21-vaccines-12-01452" ref-type="bibr">21</xref>,<xref rid="B23-vaccines-12-01452" ref-type="bibr">23</xref>].</p><p>In Spain, the COVID-19 pandemic impacted measles epidemiology in much the same way as it did in neighboring countries, with a drastic reduction in case reports since the first lockdown, as well as in 2021 (two cases) and 2022 (one case). For vaccination coverage, first-dose data, which had traditionally remained above 95% at both national and regional levels since 2000, decreased in some regions to below 90% in 2021, but remained above 95% at a national level [<xref rid="B14-vaccines-12-01452" ref-type="bibr">14</xref>]. Vaccination coverage with two doses, which traditionally ranged around 90%, was even more affected. However, thanks to the uptake and vaccination efforts made by the Autonomous Regions, vaccination coverage in 2022 was similar to the rates recorded prior to the pandemic [<xref rid="B24-vaccines-12-01452" ref-type="bibr">24</xref>,<xref rid="B25-vaccines-12-01452" ref-type="bibr">25</xref>].</p><p>In the current epidemiologic situation here in Spain, the probability of exposure to the measles virus is extremely random. A susceptible person can spend years, or even a lifetime, without being exposed to the virus, especially if he/she lives in rural areas and travels little. The reported cases are, therefore, neither representative of nor proportional to the susceptible population, as the opportunity for exposure depends on other factors, such as population density, intra-group population dynamics, or the heterogeneity of the origin of the population. Reported measles cases are, therefore, a &#x02018;raw&#x02019; indicator of the level of susceptibility of the population group to which the case belongs. The WHO estimates that if the level of susceptibility in a population is above 5%, there is a risk of measles spread and a threat to the elimination status [<xref rid="B26-vaccines-12-01452" ref-type="bibr">26</xref>].</p><p>In our study, the proportion of measles cases in foreign-born subjects accounted for 18.6% of all reported cases, while in the same period of time, the percentage of foreign-born people in the general population was 13.8%. The foreign population resident in Spain increased by 25.5% (more than 1.5 million people), rising from 12.8% in 2014 to 15.7% in 2022 [<xref rid="B19-vaccines-12-01452" ref-type="bibr">19</xref>]. In 2022, Spain registered one of the highest entry rates into the European Region in terms of foreigners per 100,000 inhabitants, and ranks fourth globally in the reception of permanent immigrants [<xref rid="B27-vaccines-12-01452" ref-type="bibr">27</xref>].</p><p>The age distribution of cases shows differences when stratified by place of origin. High rates in children under 5 years of age born abroad are explained both by the low denominator and by vaccination schedules in the countries of origin, where the second dose of MMR is usually given from the age of 5 onwards [<xref rid="B28-vaccines-12-01452" ref-type="bibr">28</xref>]. The group of migrants aged 5&#x02013;29 years has an incidence rate which is double that of people of this age born in Spain, and is thus a vulnerable group that requires special attention when it comes to measles.</p><p>Studies have shown that the immune status related to measles among migrants in Europe is worse than that of the native resident population, mainly because they have not received the doses or potential MMR boosters in their home countries [<xref rid="B29-vaccines-12-01452" ref-type="bibr">29</xref>]. In our study, the proportion of imported cases was significantly higher among people born outside Spain (23.6% vs. 6.1%), which can be explained by the fact that it is common among the resident foreign population to travel to their countries of origin, or to interact with family or friends coming from those countries, so that the risk of exposure to the virus, if it still continues to circulate in their country, is higher.</p><p>On the other hand, there is evidence of increased vaccine hesitancy among migrants, partly because xenophobic feelings of the native population reduce confidence in the health system of the country of arrival, thus intensifying anti-vaccination sentiments among migrants [<xref rid="B30-vaccines-12-01452" ref-type="bibr">30</xref>], which may in turn lead to outbreaks of immune-preventable diseases, even in places with high vaccination coverages [<xref rid="B31-vaccines-12-01452" ref-type="bibr">31</xref>].</p><p>The WHO Global Action Plan to Promote the Health of Refugees and Migrants, 2019&#x02013;2023, flags the potential for the host countries&#x02019; own legal systems to be a source of inequities in access to health resources for these vulnerable groups [<xref rid="B32-vaccines-12-01452" ref-type="bibr">32</xref>]. It is, therefore, necessary to engage in self-criticism and assess any potential impediments barring access to health resources as well as the timeliness and appropriateness of the health information provided to these population groups.</p><p>For some Spanish geographic areas, it should be borne in mind that there are population groups with anti-vaccination feelings fed by people from European countries where these movements are common, such as in the Canary Islands and Balearic Isles [<xref rid="B33-vaccines-12-01452" ref-type="bibr">33</xref>].</p><p>As far as the source continents are concerned, while more than 50% of the migrant population during the study period came from Latin America, barely 25% of measles cases were born there. In contrast, 55.9% of all measles cases reported across the study period and born abroad were of European origin. The countries with the highest number of cases were Romania, Italy and Ukraine. In Romania and Ukraine, measles has been endemic, and they have experienced major epidemics for several years with overwhelming public health consequences.</p><p>In Romania, MMR is given at ages 12 months and 5 years [<xref rid="B28-vaccines-12-01452" ref-type="bibr">28</xref>]. Since 2014, vaccination coverage with one MMR dose has barely reached 89%, falling to 83% in 2022 [<xref rid="B10-vaccines-12-01452" ref-type="bibr">10</xref>]. Susceptible pockets have been reflected in the explosion of cases reported between 2016 and 2020. In 2023, more than half of the cases were under 5 years old, mostly unvaccinated [<xref rid="B34-vaccines-12-01452" ref-type="bibr">34</xref>]. That year, the Romanian community in Spain accounted for 1.1% of the total population, with around 540,000 inhabitants [<xref rid="B19-vaccines-12-01452" ref-type="bibr">19</xref>].</p><p>Consideration should be given to the possibility that some of the migrants of Romanian origin also present the added challenge of belonging to the Roma community. The possible condition of associated marginality could not only render it more difficult for the health system to identify them, but also make for poor access to healthcare services [<xref rid="B35-vaccines-12-01452" ref-type="bibr">35</xref>]. This might better explain their lower vaccination coverage vis-&#x000e0;-vis native populations, than would refusal of vaccination due to anti-vaccination feelings [<xref rid="B30-vaccines-12-01452" ref-type="bibr">30</xref>].</p><p>Italy has included MMR administration at ages 12 months and 5/6 years in its vaccination schedule [<xref rid="B28-vaccines-12-01452" ref-type="bibr">28</xref>], and in 2023, was able to prove that measles virus circulation had been interrupted for 12 months [<xref rid="B11-vaccines-12-01452" ref-type="bibr">11</xref>]. However, from 2017 to 2020 it experienced major outbreaks, with about 8500 cases. While first-dose vaccination coverage has never actually reached 95%, with values remaining closer to 90%, since 2021, this target figure has been approached [<xref rid="B10-vaccines-12-01452" ref-type="bibr">10</xref>].</p><p>The flow of people from Ukraine to Spain has greatly increased since the beginning of the conflict (rising from an inward-bound figure of 9836 in 2021 to one of 85,978 in 2022), with the under-15 age group accounting for around 33% of all arrivals in 2022 [<xref rid="B36-vaccines-12-01452" ref-type="bibr">36</xref>]. Although Ukraine administers MMR to children at the ages of 12 months and 6 years [<xref rid="B28-vaccines-12-01452" ref-type="bibr">28</xref>], vaccination coverage was already below 80% before the war with Russia (in 2016, it fell to 42%) [<xref rid="B37-vaccines-12-01452" ref-type="bibr">37</xref>]. Political instability, as well as mass and social media-backed efforts to undermine the health system, and vaccination campaigns in particular, led to an increase in anti-vaccination feelings in the country [<xref rid="B37-vaccines-12-01452" ref-type="bibr">37</xref>]. This, coupled with the difficulties in accessing health services resulting from the war that began in 2022, keeps the country in a difficult situation regarding immunity to immune-preventable diseases, such as measles. The direct consequence of the decline in population immunity was an exponential increase in cases, outbreaks and even deaths during the 2018&#x02013;2019 measles epidemic, with more than 110,000 cases and 40 associated deaths [<xref rid="B37-vaccines-12-01452" ref-type="bibr">37</xref>,<xref rid="B38-vaccines-12-01452" ref-type="bibr">38</xref>].</p><p>Since 2019, both the Common Immunization Schedule throughout life [<xref rid="B13-vaccines-12-01452" ref-type="bibr">13</xref>] and the Accelerated Vaccination Schedule [<xref rid="B39-vaccines-12-01452" ref-type="bibr">39</xref>], which is applied in situations such as those with a migrant or displaced population, have been published annually. In Spain, the healthcare competencies are transferred to the autonomous communities, which are responsible for identifying vulnerable population groups. Vaccination of immigrants is included in primary care programs, and any contact with the health system is used as an opportunity to update vaccinations (e.g., pertussis vaccination in pregnant women or MMR vaccination after childbirth). For the specific case of Ukrainian war refugees, an Action Guide was issued in 2022 in response to the arrival of displaced persons from Ukraine [<xref rid="B40-vaccines-12-01452" ref-type="bibr">40</xref>], setting out this population&#x02019;s vulnerable status and the measures to be taken in terms of vaccination, all of which were detailed in a specific document [<xref rid="B41-vaccines-12-01452" ref-type="bibr">41</xref>]. Our results suggest that, in general, the resident population of foreign origin has a worse vaccination status than that born in Spain. However, one possible bias could be the underreporting of vaccination status among migrants, which is higher than among Spain-born cases (15.7% vs. 10.6%; <italic toggle="yes">p</italic> = 0.022) (<xref rid="vaccines-12-01452-t001" ref-type="table">Table 1</xref>).</p><p>The results of the second seroprevalence study, based on data from 2017&#x02013;2018 [<xref rid="B42-vaccines-12-01452" ref-type="bibr">42</xref>], are consistent with the distribution of measles cases in the current phase. In terms of immune status with respect to measles, people who were born from 1988 to1997, and at the time of data-collection were 20 to 29 years old, had an antibody titer level of below 87%. These are the traditionally susceptible cohorts, meaning that they did not have the opportunity to receive the vaccine because of the low initial coverage after its inclusion in the calendar, and were at the same time less likely to develop natural antibodies due to the decline in the incidence of the disease, limiting their possibility of exposure to the wild virus [<xref rid="B24-vaccines-12-01452" ref-type="bibr">24</xref>]. It was noted that there were greater differences between those born in and outside Spain, in cohorts born between 1988 and 1997, among whom the percentage of seropositivity for measles is lower. These differences are not significant, however, and in addition, the sample was too small for disaggregated age group calculations [<xref rid="B42-vaccines-12-01452" ref-type="bibr">42</xref>].</p><p>Anti-vaccination feelings or vaccination hesitancy in the country of origin accompany migrants or displaced persons to the destination country and pose an additional challenge to health systems and host professionals. At the 65th World Health Assembly in 2022, a report was presented by the Behavioral Sciences for Better Health Initiative [<xref rid="B43-vaccines-12-01452" ref-type="bibr">43</xref>], with the aim of promoting the systematic use of behavioral and social sciences in public health. This initiative aims to broaden the health approach by improving understanding of people&#x02019;s health behaviors, so as to be able to design more effective interventions. This approach from the social and behavioral sciences needs to be incorporated as an essential element in public health interventions in general, and in health vulnerable groups in particular. The case of the displaced Ukrainian population is an example of where such an approach could be applied.</p><p>The assumption that the resident population of foreign origin generally has a worse immune status than that of the host country [<xref rid="B44-vaccines-12-01452" ref-type="bibr">44</xref>], especially if the latter is in the post-elimination phase, should not only be made with caution, but should also take into account the vaccination coverage of the country of origin and its elimination status. In Spain, most of the resident migrant population comes from Latin America, but this does not translate into a proportional number of cases, due to the virus&#x02019; limited circulation in that region for a good number of years (elimination of measles having been declared for that region in 2002). Nonetheless, it is true that countries such as Colombia, the country of origin of the majority of cases of measles of American origin in this study (10; 5.6%), has barely achieved 95% coverage with one MMR dose since 2014 (in 2018 and again in 2019), falling below this figure even before the pandemic [<xref rid="B45-vaccines-12-01452" ref-type="bibr">45</xref>].</p><p>Catalonia and the Autonomous Region of Valencia are the regions with the highest percentage of total cases and cases reported in people born outside Spain during the study period. This could be due to the wider variety of origins of the immigrant population in these regions, to the increased transit of international flights, or to different population dynamics still to be examined.</p><p>During the post-elimination period, it takes an average of 6 years from arrival in Spain for the resident population of foreign origin to become infected with measles (4 years, if subjects are in the 5&#x02013;29 age group). In the case of school-age children, the active work of the health system in recruiting vaccine candidates is of particular importance.</p><p>Spain is increasingly a country of reception of migrant populations, with the potential risk of generating health inequities. The system needs to undergo a review to assess whether migrants&#x02019; potential contacts with the health sector are being sufficiently exploited to offer them vaccination (e.g., when they are about to make an international trip, such as to their country of origin; by bringing children to the pediatrician; or when they make a medical visit for other health reasons) [<xref rid="B46-vaccines-12-01452" ref-type="bibr">46</xref>]. While this measure is included in the Strategic Plan for Measles Elimination for the general population [<xref rid="B9-vaccines-12-01452" ref-type="bibr">9</xref>], the particular vulnerability of this population group should be emphasized. In this regard, health professionals are key, both in identifying susceptible individuals and in conducting health education and promoting correct vaccination.</p><p>Health personnel should receive continuous and up-to-date training in vaccination schedules and the implementation of accelerated guidelines if needed, and be made aware of the importance of maintaining the measles elimination status here in Spain. Finally, this policy should be complemented by incorporating the views of professionals in behavioral and social sciences, as proposed by the WHO initiative, in order to comprehensively address barriers linked to health behaviors, such as vaccine hesitancy.</p></sec><sec sec-type="conclusions" id="sec5-vaccines-12-01452"><title>5. Conclusions</title><p>This study shows that during the post-elimination period, the incidence of measles is 40% higher in Spain&#x02019;s foreign-born population than in its native-born population. In the migrant population, the median time from arrival in Spain to contracting measles is estimated at approximately 6 years. More than 50% of measles cases in the migrant population are of European origin. Lastly, the regions with the highest number of reported measles cases as well as the highest rates of foreign residents are Catalonia and Valencia.</p><p>Despite the fact that one of the current challenges facing Spain is the increase in migratory flows, health systems (including epidemiological surveillance and laboratory systems) have managed to maintain the elimination status of the disease.</p><p>All efforts must be directed at any potentially susceptible person. The health system is responsible for identifying the most vulnerable groups so that specific intervention measures can be designed, such as reviewing the vaccination schedule of anyone born outside Spain upon arrival or improving the collaboration with migrants&#x02019; communities and the health system, which will help mitigate susceptibility to measles and thus maintain the current elimination status.</p></sec></body><back><ack><title>Acknowledgments</title><p>We sincerely thank all physicians, epidemiologists and microbiologists involved in the National Epidemiological Surveillance Network (RENAVE) from all Autonomous Regions in Spain, for their commitment to surveillance and the goal of measles elimination.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-vaccines-12-01452"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/vaccines12121452/s1">https://www.mdpi.com/article/10.3390/vaccines12121452/s1</uri>. Table S1: Measles cases and crude incidence rates by birth origin and region, Spain, 2014&#x02013;2022; Figure S1: Geographical distribution of measles cases (%) by birth origin and region, Spain, 2014&#x02013;2022.</p><supplementary-material id="vaccines-12-01452-s001" position="float" content-type="local-data"><media xlink:href="vaccines-12-01452-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization N.L.-P., T.L.-C., A.F.-G., J.E.E. and J.M.-C.; methodology, N.L.-P., T.L.-C. and J.M.-C.; formal analysis, N.L.-P. and T.L.-C.; data curation, N.L.-P. and T.L.-C.; writing&#x02014;original draft preparation, N.L.-P., T.L.-C. and J.M.-C.; writing&#x02014;review and editing, N.L.-P., T.L.-C., A.F.-G., J.E.E. and J.M.-C.; supervision, T.L.-C. and J.M.-C.; software, N.L.-P. and T.L.-C.; All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Informed Consent Statement</title><p>Ethical review and approval were waived for this study upon request to an ethics committee as the confidentiality of the cases is not compromised and their anonymity is always guaranteed. Council of the European Union (2016). Position of the Council at first reading with a view to the adoption of a Regulation of the European Parliament and of the Council on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation). Official Journal of the European Union, Espa&#x000f1;a. (2018). Ley Org&#x000e1;nica 3/2018, de 5 de diciembre, de Protecci&#x000f3;n de Datos Personales y garant&#x000ed;a de los derechos digitales. Bolet&#x000ed;n Oficial del Estado, n&#x000fa;m. 294, de 6 de diciembre de 2018, disposici&#x000f3;n adicional decimos&#x000e9;ptima.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data presented in this study are partially available on request from the corresponding author due to the data are collected as part of mandatory surveillance to provide information for the National Measles Elimination Plan. Most of the individualised information is restricted and is only allowed to be handled as aggregated analysis.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-vaccines-12-01452"><label>1.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group><article-title>Forty-First World Health Assembly. Resolutions and Annexes. Geneve. May 1988; p. 72</article-title><comment>Available online: <ext-link xlink:href="https://iris.who.int/bitstream/handle/10665/164197/WHA41_1988-REC-1_eng.pdf?sequence=1&#x00026;isAllowed=y" ext-link-type="uri">https://iris.who.int/bitstream/handle/10665/164197/WHA41_1988-REC-1_eng.pdf?sequence=1&#x00026;isAllowed=y</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-04">(accessed on 4 November 2024)</date-in-citation></element-citation></ref><ref id="B2-vaccines-12-01452"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de Quadros</surname><given-names>C.A.</given-names></name>
<name><surname>Andrus</surname><given-names>J.K.</given-names></name>
<name><surname>Danovaro-Holliday</surname><given-names>M.C.</given-names></name>
<name><surname>Castillo-Sol&#x000f3;rzano</surname><given-names>C.</given-names></name>
</person-group><article-title>Feasibility of global measles eradication after interruption of transmission in the Americas</article-title><source>Expert. Rev. Vaccines</source><year>2008</year><volume>7</volume><fpage>355</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1586/14760584.7.3.355</pub-id><pub-id pub-id-type="pmid">18393605</pub-id>
</element-citation></ref><ref id="B3-vaccines-12-01452"><label>3.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>WHO</collab>
</person-group><article-title>WHO News. A 30-Fold Rise of Measles Cases in 2023 in the WHO European Region Warrants Urgent Action</article-title><year>2023</year><comment>Available online: <ext-link xlink:href="https://www.who.int/europe/news/item/14-12-2023-a-30-fold-rise-of-measles-cases-in-2023-in-the-who-european-region-warrants-urgent-action" ext-link-type="uri">https://www.who.int/europe/news/item/14-12-2023-a-30-fold-rise-of-measles-cases-in-2023-in-the-who-european-region-warrants-urgent-action</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-25">(accessed on 25 September 2024)</date-in-citation></element-citation></ref><ref id="B4-vaccines-12-01452"><label>4.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group><article-title>Measles&#x02014;A Strategic Framework for the Elimination of Measles in the European Region</article-title><year>1999</year><comment>Available online: <ext-link xlink:href="https://iris.who.int/handle/10665/108278" ext-link-type="uri">https://iris.who.int/handle/10665/108278</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-25">(accessed on 25 September 2024)</date-in-citation></element-citation></ref><ref id="B5-vaccines-12-01452"><label>5.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>WHO</collab>
</person-group><article-title>Regional Office for Europe Eliminating Measles and Rubella in the WHO European Region; Integrated Guidance for Surveillance, Outbreak Response and Verification of Elimination</article-title><year>2024</year><comment>Available online: <ext-link xlink:href="https://iris.who.int/bitstream/handle/10665/375923/9789289060783-eng.pdf?sequence=1" ext-link-type="uri">https://iris.who.int/bitstream/handle/10665/375923/9789289060783-eng.pdf?sequence=1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-25">(accessed on 25 September 2024)</date-in-citation></element-citation></ref><ref id="B6-vaccines-12-01452"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Minta</surname><given-names>A.A.</given-names></name>
<name><surname>Ferrari</surname><given-names>M.</given-names></name>
<name><surname>Antoni</surname><given-names>S.</given-names></name>
<name><surname>Portnoy</surname><given-names>A.</given-names></name>
<name><surname>Sbarra</surname><given-names>A.</given-names></name>
<name><surname>Lambert</surname><given-names>B.</given-names></name>
<name><surname>Hatcher</surname><given-names>C.</given-names></name>
<name><surname>Hsu</surname><given-names>C.H.</given-names></name>
<name><surname>Ho</surname><given-names>L.L.</given-names></name>
<name><surname>Steulet</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Progress Toward Measles Elimination&#x02014;Worldwide, 2000&#x02013;2022</article-title><source>Morb. Mortal. Wkly. Rep.</source><year>2023</year><volume>72</volume><fpage>1262</fpage><lpage>1268</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm7246a3</pub-id><pub-id pub-id-type="pmid">37971951</pub-id>
</element-citation></ref><ref id="B7-vaccines-12-01452"><label>7.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>European Centre for Disease Prevention and Control</collab>
</person-group><source>Measles on the Rise in the EU/EEA: Considerations for Public Health Response</source><publisher-name>ECDC</publisher-name><publisher-loc>Stockholm, Sweden</publisher-loc><year>2024</year><comment>Available online: <ext-link xlink:href="https://www.ecdc.europa.eu/sites/default/files/documents/measles-eu-threat-assessment-brief-february-2024.pdf" ext-link-type="uri">https://www.ecdc.europa.eu/sites/default/files/documents/measles-eu-threat-assessment-brief-february-2024.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-26">(accessed on 26 September 2024)</date-in-citation></element-citation></ref><ref id="B8-vaccines-12-01452"><label>8.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>Centro Nacional de Epidemiolog&#x000ed;a</collab>
</person-group><article-title>Instituto de Salud Carlos III</article-title><source>Plan de Eliminaci&#x000f3;n del Sarampi&#x000f3;n en Espa&#x000f1;a. Madrid.</source><year>2000</year><comment>Available online: <ext-link xlink:href="http://gesdoc.isciii.es/gesdoccontroller?action=download&#x00026;id=19/10/2012-f2327d5909" ext-link-type="uri">http://gesdoc.isciii.es/gesdoccontroller?action=download&#x00026;id=19/10/2012-f2327d5909</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-25">(accessed on 25 September 2024)</date-in-citation></element-citation></ref><ref id="B9-vaccines-12-01452"><label>9.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>Consejo Interterritorial del Sistema Nacional de Salud</collab>
</person-group><article-title>Ministerio de Sanidad Plan Estrat&#x000e9;gico Para la Eliminaci&#x000f3;n Del Sarampi&#x000f3;n y La Rubeola en Espa&#x000f1;a 2021&#x02013;2025</article-title><year>2021</year><comment>Available online: <ext-link xlink:href="https://www.sanidad.gob.es/areas/promocionPrevencion/vacunaciones/sarampion-rubeola/docs/PlanEstrategico_SarampionyRubeola.pdf" ext-link-type="uri">https://www.sanidad.gob.es/areas/promocionPrevencion/vacunaciones/sarampion-rubeola/docs/PlanEstrategico_SarampionyRubeola.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-25">(accessed on 25 September 2024)</date-in-citation></element-citation></ref><ref id="B10-vaccines-12-01452"><label>10.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>WHO (World Health Organization)</collab>
</person-group><article-title>Comparison of Reported Cases for Measles and Immunization Coverage for Measles Vaccination Coverage</article-title><year>2024</year><comment>Available online: <ext-link xlink:href="https://immunizationdata.who.int/compare?CODE=ROU&#x00026;COMPARISON=type1__WIISE/MT_AD_INC_LONG+type2__WIISE/MT_AD_COV_LONG+option1__MEASLES_cases+option2__MCV_coverage&#x00026;YEAR=" ext-link-type="uri">https://immunizationdata.who.int/compare?CODE=ROU&#x00026;COMPARISON=type1__WIISE/MT_AD_INC_LONG+type2__WIISE/MT_AD_COV_LONG+option1__MEASLES_cases+option2__MCV_coverage&#x00026;YEAR=</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-10-31">(accessed on 31 October 2024)</date-in-citation></element-citation></ref><ref id="B11-vaccines-12-01452"><label>11.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>WHO</collab>
<collab>Regional Office for Europe</collab>
</person-group><article-title>Twelfth Meeting of the European Regional Verification Commission for Measles and Rubella Elimination, Copenhagen, Denmark, 8&#x02013;11 September 2023; Meeting Report, Report No.: WHO/EURO:2024-9722-49494-74055</article-title><year>2024</year><comment>Available online: <ext-link xlink:href="https://iris.who.int/bitstream/handle/10665/376606/WHO-EURO-2024-9722-49494-74055-eng.pdf?sequence=1" ext-link-type="uri">https://iris.who.int/bitstream/handle/10665/376606/WHO-EURO-2024-9722-49494-74055-eng.pdf?sequence=1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-30">(accessed on 30 September 2024)</date-in-citation></element-citation></ref><ref id="B12-vaccines-12-01452"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hagstam</surname><given-names>P.</given-names></name>
<name><surname>B&#x000f6;ttiger</surname><given-names>B.</given-names></name>
<name><surname>Winqvist</surname><given-names>N.</given-names></name>
</person-group><article-title>Measles and rubella seroimmunity in newly arrived adult immigrants in Sweden</article-title><source>Infect. Dis.</source><year>2019</year><volume>51</volume><fpage>122</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1080/23744235.2018.1524583</pub-id><pub-id pub-id-type="pmid">30676125</pub-id>
</element-citation></ref><ref id="B13-vaccines-12-01452"><label>13.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>Consejo Interterritorial del Sistema Nacional de Salud</collab>
</person-group><article-title>Ministerio de Sanidad Calendario de Vacunaci&#x000f3;n a lo Largo de Toda la Vida</article-title><year>2024</year><comment>Available online: <ext-link xlink:href="https://www.sanidad.gob.es/areas/promocionPrevencion/vacunaciones/calendario/calendario/docs/CalendarioVacunacion_Todalavida_2024.pdf" ext-link-type="uri">https://www.sanidad.gob.es/areas/promocionPrevencion/vacunaciones/calendario/calendario/docs/CalendarioVacunacion_Todalavida_2024.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-25">(accessed on 25 September 2024)</date-in-citation></element-citation></ref><ref id="B14-vaccines-12-01452"><label>14.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>Centro de Coordinaci&#x000f3;n de Alertas y Emergencias Sanitarias</collab>
<collab>Ministerio de Sanidad</collab>
</person-group><article-title>Evaluaci&#x000f3;n R&#x000e1;pida de Riesgo. Implicaciones para Espa&#x000f1;a del Aumento de Casos y Brotes de Sarampi&#x000f3;n a Nivel Mundial y Europeo</article-title><year>2024</year><comment>Available online: <ext-link xlink:href="https://www.sanidad.gob.es/areas/alertasEmergenciasSanitarias/alertasActuales/sarampion/docs/20240617_Sarampion_ERR.pdf" ext-link-type="uri">https://www.sanidad.gob.es/areas/alertasEmergenciasSanitarias/alertasActuales/sarampion/docs/20240617_Sarampion_ERR.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-25">(accessed on 25 September 2024)</date-in-citation></element-citation></ref><ref id="B15-vaccines-12-01452"><label>15.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>WHO</collab>
</person-group><article-title>Seventy-Second World Health Assembly. Decisions: WHA72(14). Promoting the Health of Refugees and Migrants 2019</article-title><comment>Available online: <ext-link xlink:href="https://apps.who.int/gb/ebwha/pdf_files/WHA72-REC1/A72_2019_REC1-en.pdf" ext-link-type="uri">https://apps.who.int/gb/ebwha/pdf_files/WHA72-REC1/A72_2019_REC1-en.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-07-24">(accessed on 24 July 2024)</date-in-citation></element-citation></ref><ref id="B16-vaccines-12-01452"><label>16.</label><element-citation publication-type="webpage"><article-title>Global Action Plan on Promoting the Health of Refugees and Migrants, 2019&#x02013;2023 (Annex 5)</article-title><year>2019</year><comment>Available online: <ext-link xlink:href="https://www.who.int/publications/i/item/WHA72-2019-REC-1" ext-link-type="uri">https://www.who.int/publications/i/item/WHA72-2019-REC-1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-07-24">(accessed on 24 July 2024)</date-in-citation></element-citation></ref><ref id="B17-vaccines-12-01452"><label>17.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group><article-title>Extension of the WHO Global Action Plan on Promoting the Health of Refugees and Migrants, 2019&#x02013;2023 to 2030</article-title><year>2023</year><comment>Available online: <ext-link xlink:href="https://apps.who.int/gb/ebwha/pdf_files/EB152/B152(17)-en.pdf" ext-link-type="uri">https://apps.who.int/gb/ebwha/pdf_files/EB152/B152(17)-en.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-07-24">(accessed on 24 July 2024)</date-in-citation></element-citation></ref><ref id="B18-vaccines-12-01452"><label>18.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>Ministerio de Sanidad</collab>
</person-group><article-title>y Consumo Real Decreto 2210/1995, de 28 de Diciembre, Por el Que se Crea la red Nacional de Vigilancia Epidemiol&#x000f3;gica. 1 July 1996</article-title><comment>Available online: <ext-link xlink:href="https://www.boe.es/eli/es/rd/1995/12/28/2210/con" ext-link-type="uri">https://www.boe.es/eli/es/rd/1995/12/28/2210/con</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-25">(accessed on 25 September 2024)</date-in-citation></element-citation></ref><ref id="B19-vaccines-12-01452"><label>19.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>INEbase</collab>
</person-group><article-title>Poblaci&#x000f3;n Residente Por Fecha, Sexo y Edad; Instituto Nacional de Estad&#x000ed;stica: Madrid, Spain</article-title><comment>Available online: <ext-link xlink:href="https://www.ine.es/jaxiT3/Tabla.htm?t=9681&#x00026;L=0" ext-link-type="uri">https://www.ine.es/jaxiT3/Tabla.htm?t=9681&#x00026;L=0</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-25">(accessed on 25 September 2024)</date-in-citation></element-citation></ref><ref id="B20-vaccines-12-01452"><label>20.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group><article-title>Measles Outbreaks Strategic Response Plan: 2021&#x02013;2023: Measles Outbreak Prevention, Preparedness, Response and Recovery. 2021; p. 34</article-title><comment>Available online: <ext-link xlink:href="https://apps.who.int/iris/bitstream/handle/10665/340657/9789240018600-eng.pdf?sequence=1&#x00026;isAllowed=y" ext-link-type="uri">https://apps.who.int/iris/bitstream/handle/10665/340657/9789240018600-eng.pdf?sequence=1&#x00026;isAllowed=y</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-02-14">(accessed on 14 February 2021)</date-in-citation></element-citation></ref><ref id="B21-vaccines-12-01452"><label>21.</label><element-citation publication-type="webpage"><article-title>WHO Regional Office for Europe WHO EpiBrief: A Report on the Epidemiology of Selected Vaccine-Preventable Diseases in the European Region: No. 1/2024</article-title><year>2024</year><comment>Available online: <ext-link xlink:href="https://iris.who.int/bitstream/handle/10665/378202/WHO-EURO-2024-10248-50020-75273-eng.pdf?sequence=1" ext-link-type="uri">https://iris.who.int/bitstream/handle/10665/378202/WHO-EURO-2024-10248-50020-75273-eng.pdf?sequence=1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-24">(accessed on 24 September 2024)</date-in-citation></element-citation></ref><ref id="B22-vaccines-12-01452"><label>22.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>WHO Regional Office for Europe</collab>
</person-group><article-title>Eleventh Meeting of the European Regional Verification Commission for Measles and Rubella Elimination, Copenhagen, Denmark, 8&#x02013;10 November 2022; Report No.: WHO/EURO:2024-9722-49494-74055</article-title><year>2023</year><comment>Available online: <ext-link xlink:href="https://iris.who.int/bitstream/handle/10665/370182/WHO-EURO-2023-7719-47486-69809-eng.pdf?sequence=1" ext-link-type="uri">https://iris.who.int/bitstream/handle/10665/370182/WHO-EURO-2023-7719-47486-69809-eng.pdf?sequence=1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-30">(accessed on 30 September 2024)</date-in-citation></element-citation></ref><ref id="B23-vaccines-12-01452"><label>23.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>WHO</collab>
</person-group><article-title>Europe Measles and Rubella Monthly Update&#x02014;WHO European Region</article-title><comment>Available online: <ext-link xlink:href="https://cdn.who.int/media/docs/librariesprovider2/euro-health-topics/vaccines-and-immunization/eur_mr_monthly-_update_en_august-2024.pdf?sfvrsn=36799208_2&#x00026;download=true" ext-link-type="uri">https://cdn.who.int/media/docs/librariesprovider2/euro-health-topics/vaccines-and-immunization/eur_mr_monthly-_update_en_august-2024.pdf?sfvrsn=36799208_2&#x00026;download=true</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-24">(accessed on 24 September 2024)</date-in-citation></element-citation></ref><ref id="B24-vaccines-12-01452"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>L&#x000f3;pez-Perea</surname><given-names>N.</given-names></name>
</person-group><article-title>Measles again?</article-title><source>Med. Clin.</source><year>2024</year><volume>163</volume><fpage>344</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1016/j.medcli.2024.05.021</pub-id><pub-id pub-id-type="pmid">39153945</pub-id>
</element-citation></ref><ref id="B25-vaccines-12-01452"><label>25.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>Ministerio de Sanidad</collab>
</person-group><article-title>Portal Estad&#x000ed;stico. Area de Inteligencia de Gesti&#x000f3;n. SIVAMIN. Coberturas de Vacunaci&#x000f3;n en Espa&#x000f1;a</article-title><comment>Available online: <ext-link xlink:href="https://pestadistico.inteligenciadegestion.sanidad.gob.es/publicoSNS/I/sivamin/sivamin" ext-link-type="uri">https://pestadistico.inteligenciadegestion.sanidad.gob.es/publicoSNS/I/sivamin/sivamin</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-03-26">(accessed on 26 March 2024)</date-in-citation></element-citation></ref><ref id="B26-vaccines-12-01452"><label>26.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>WHO</collab>
</person-group><article-title>Europe Verification of Measles and Rubella Elimination in the WHO European Region. July 2019</article-title><comment>Available online: <ext-link xlink:href="https://cdn.who.int/media/docs/librariesprovider2/euro-health-topics/vaccines-and-immunization/eu_mr_elimination_verfication_en_2019.pdf?sfvrsn=eb6b1aa9_2&#x00026;download=true" ext-link-type="uri">https://cdn.who.int/media/docs/librariesprovider2/euro-health-topics/vaccines-and-immunization/eu_mr_elimination_verfication_en_2019.pdf?sfvrsn=eb6b1aa9_2&#x00026;download=true</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-25">(accessed on 25 September 2024)</date-in-citation></element-citation></ref><ref id="B27-vaccines-12-01452"><label>27.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<name><surname>Cuadrado</surname><given-names>P.</given-names></name>
<name><surname>Sastres</surname><given-names>T.</given-names></name>
<name><surname>&#x000c1;ngel</surname><given-names>L.</given-names></name>
</person-group><article-title>Comparing the Characteristics of Migratory Flows to Spain and Other European Union Countries; Economic Bulletin/Banco de Espa&#x000f1;a; 2024/Q3; Article 06. 7 August 2024; 12p</article-title><comment>Available online: <ext-link xlink:href="https://www.google.com/url?sa=t&#x00026;source=web&#x00026;rct=j&#x00026;opi=89978449&#x00026;url=https://www.bde.es/f/webbe/SES/Secciones/Publicaciones/InformesBoletinesRevistas/BoletinEconomico/24/T3/Files/be2403-art06e.pdf&#x00026;ved=2ahUKEwjcovWZ8bWKAxVwR2wGHY4xJKUQFnoECBkQAw&#x00026;usg=AOvVaw2Xd_GKebb68ixYZu0Kj3rS" ext-link-type="uri">https://www.google.com/url?sa=t&#x00026;source=web&#x00026;rct=j&#x00026;opi=89978449&#x00026;url=https://www.bde.es/f/webbe/SES/Secciones/Publicaciones/InformesBoletinesRevistas/BoletinEconomico/24/T3/Files/be2403-art06e.pdf&#x00026;ved=2ahUKEwjcovWZ8bWKAxVwR2wGHY4xJKUQFnoECBkQAw&#x00026;usg=AOvVaw2Xd_GKebb68ixYZu0Kj3rS</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-25">(accessed on 25 September 2024)</date-in-citation></element-citation></ref><ref id="B28-vaccines-12-01452"><label>28.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>ECDC</collab>
</person-group><article-title>Vaccine Schedules in All Countries in the EU/EEA</article-title><comment>Available online: <ext-link xlink:href="https://vaccine-schedule.ecdc.europa.eu/" ext-link-type="uri">https://vaccine-schedule.ecdc.europa.eu/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-25">(accessed on 25 September 2024)</date-in-citation></element-citation></ref><ref id="B29-vaccines-12-01452"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cherri</surname><given-names>Z.</given-names></name>
<name><surname>Lau</surname><given-names>K.</given-names></name>
<name><surname>Nellums</surname><given-names>L.B.</given-names></name>
<name><surname>Himmels</surname><given-names>J.</given-names></name>
<name><surname>Deal</surname><given-names>A.</given-names></name>
<name><surname>McGuire</surname><given-names>E.</given-names></name>
<name><surname>Mounier-Jack</surname><given-names>S.</given-names></name>
<name><surname>Norredam</surname><given-names>M.</given-names></name>
<name><surname>Crawshaw</surname><given-names>A.</given-names></name>
<name><surname>Carter</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>The immune status of migrant populations in Europe and implications for vaccine-preventable disease control: A systematic review and meta-analysis</article-title><source>J. Travel Med.</source><year>2024</year><volume>31</volume><fpage>taae033</fpage><pub-id pub-id-type="doi">10.1093/jtm/taae033</pub-id><pub-id pub-id-type="pmid">38423523</pub-id>
</element-citation></ref><ref id="B30-vaccines-12-01452"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tankwanchi</surname><given-names>A.S.</given-names></name>
<name><surname>Bowman</surname><given-names>B.</given-names></name>
<name><surname>Garrison</surname><given-names>M.</given-names></name>
<name><surname>Larson</surname><given-names>H.</given-names></name>
<name><surname>Wiysonge</surname><given-names>C.S.</given-names></name>
</person-group><article-title>Vaccine hesitancy in migrant communities: A rapid review of latest evidence</article-title><source>Curr. Opin. Immunol.</source><year>2021</year><volume>71</volume><fpage>62</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2021.05.009</pub-id><pub-id pub-id-type="pmid">34118728</pub-id>
</element-citation></ref><ref id="B31-vaccines-12-01452"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bell</surname><given-names>S.</given-names></name>
<name><surname>Saliba</surname><given-names>V.</given-names></name>
<name><surname>Ramsay</surname><given-names>M.</given-names></name>
<name><surname>Mounier-Jack</surname><given-names>S.</given-names></name>
</person-group><article-title>What have we learnt from measles outbreaks in 3 English cities? A qualitative exploration of factors influencing vaccination uptake in Romanian and Roma Romanian communities</article-title><source>BMC Public Health</source><year>2020</year><volume>20</volume><elocation-id>381</elocation-id><pub-id pub-id-type="doi">10.1186/s12889-020-8454-x</pub-id><pub-id pub-id-type="pmid">32293379</pub-id>
</element-citation></ref><ref id="B32-vaccines-12-01452"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gostin</surname><given-names>L.O.</given-names></name>
<name><surname>Abubakar</surname><given-names>I.</given-names></name>
<name><surname>Guerra</surname><given-names>R.</given-names></name>
<name><surname>Rashid</surname><given-names>S.F.</given-names></name>
<name><surname>Friedman</surname><given-names>E.A.</given-names></name>
<name><surname>Jakab</surname><given-names>Z.</given-names></name>
</person-group><article-title>WHO takes action to promote the health of refugees and migrants</article-title><source>Lancet</source><year>2019</year><volume>393</volume><fpage>2016</fpage><lpage>2018</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(19)31051-7</pub-id><pub-id pub-id-type="pmid">31106734</pub-id>
</element-citation></ref><ref id="B33-vaccines-12-01452"><label>33.</label><element-citation publication-type="webpage"><article-title>El Sarampi&#x000f3;n Nos Llega en Avi&#x000f3;n Por Los Antivacunas de Pa&#x000ed;ses Desarrollados</article-title><year>2024</year><comment>Available online: <ext-link xlink:href="https://www.canarias7.es/sociedad/salud/sarampion-llega-avion-antivacunas-paises-desarrollados-20240425225534-nt.html?ref=https%3A%2F%2Fwww.google.com%2F" ext-link-type="uri">https://www.canarias7.es/sociedad/salud/sarampion-llega-avion-antivacunas-paises-desarrollados-20240425225534-nt.html?ref=https%3A%2F%2Fwww.google.com%2F</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-04-25">(accessed on 25 April 2024)</date-in-citation></element-citation></ref><ref id="B34-vaccines-12-01452"><label>34.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>UNICEF</collab>
</person-group><article-title>Romania Measles Cases Across Europe Continue to Surge, Putting Millions of Children at Risk. Rapid Response to Measles Outbreak Is Critical, as Cases This Year Predicted to Soon Exceed Total Number Reported in 2023</article-title><year>2024</year><comment>Available online: <ext-link xlink:href="https://www.unicef.org/romania/press-releases/measles-cases-across-europe-continue-surge-putting-millions-children-risk" ext-link-type="uri">https://www.unicef.org/romania/press-releases/measles-cases-across-europe-continue-surge-putting-millions-children-risk</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-05-28">(accessed on 28 May 2024)</date-in-citation></element-citation></ref><ref id="B35-vaccines-12-01452"><label>35.</label><element-citation publication-type="gov"><article-title>Evidence Review for the Acceptability and Effectiveness of Interventions to Increase Routine Vaccine Uptake: Vaccine Uptake in the General Population: Evidence Review J; National Institute for Health and Care Excellence (NICE): London, UK, 2022; NICE Evidence Reviews Collection</article-title><comment>Available online: <ext-link xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK581893/" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/books/NBK581893/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-08-26">(accessed on 26 August 2024)</date-in-citation></element-citation></ref><ref id="B36-vaccines-12-01452"><label>36.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<name><surname>de Prensa</surname><given-names>N.</given-names></name>
</person-group><article-title>Estad&#x000ed;stica de Migraciones y Cambios de Residencia (EMCR) A&#x000f1;o 2022</article-title><year>2023</year><comment>Available online: <ext-link xlink:href="https://www.ine.es/prensa/emcr_2022.pdf" ext-link-type="uri">https://www.ine.es/prensa/emcr_2022.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-25">(accessed on 25 September 2024)</date-in-citation></element-citation></ref><ref id="B37-vaccines-12-01452"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hill</surname><given-names>M.</given-names></name>
<name><surname>Vanderslott</surname><given-names>S.</given-names></name>
<name><surname>Volokha</surname><given-names>A.</given-names></name>
<name><surname>Pollard</surname><given-names>A.J.</given-names></name>
</person-group><article-title>Addressing vaccine inequities among Ukrainian refugees</article-title><source>Lancet Infect. Dis.</source><year>2022</year><volume>22</volume><fpage>935</fpage><lpage>936</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(22)00366-8</pub-id><pub-id pub-id-type="pmid">35752178</pub-id>
</element-citation></ref><ref id="B38-vaccines-12-01452"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Orsini</surname><given-names>D.</given-names></name>
<name><surname>Martini</surname><given-names>M.</given-names></name>
</person-group><article-title>Measles: A new danger for Ukraine&#x02019;s children! The need for an effective and timely vaccination prevention campaign for an insidious disease that comes from afar</article-title><source>J. Prev. Med. Hyg.</source><year>2023</year><volume>64</volume><fpage>e204</fpage><lpage>e208</lpage><pub-id pub-id-type="doi">10.15167/2421-4248/jpmh2023.64.2.2996</pub-id><pub-id pub-id-type="pmid">37654850</pub-id>
</element-citation></ref><ref id="B39-vaccines-12-01452"><label>39.</label><element-citation publication-type="webpage"><article-title>Ponencia de Programa y Registro de Vacunaciones. Comisi&#x000f3;n de Salud P&#x000fa;blica; del Consejo Interterritorial del Sistema Nacional de Salud. Ministerio de Sanidad; Ponencia de Programa y Registro de Vacunaciones Calendario Acelerado de Vacunaciones</article-title><year>2023</year><comment>Available online: <ext-link xlink:href="https://www.sanidad.gob.es/areas/promocionPrevencion/vacunaciones/calendario/docs/Calendario_Acelerado_Vacunaciones.pdf" ext-link-type="uri">https://www.sanidad.gob.es/areas/promocionPrevencion/vacunaciones/calendario/docs/Calendario_Acelerado_Vacunaciones.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-04">(accessed on 4 November 2024)</date-in-citation></element-citation></ref><ref id="B40-vaccines-12-01452"><label>40.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>Ministerio de Sanidad</collab>
</person-group><article-title>Gu&#x000ed;a de Actuaci&#x000f3;n ante la Llegada de Desplazados Desde Ucrania</article-title><year>2022</year><comment>Available online: <ext-link xlink:href="https://www.sanidad.gob.es/gabinetePrensa/ucrania/docs/Guia_de_actuacion_desplazados-Ucrania_18.03.2022.pdf" ext-link-type="uri">https://www.sanidad.gob.es/gabinetePrensa/ucrania/docs/Guia_de_actuacion_desplazados-Ucrania_18.03.2022.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-25">(accessed on 25 September 2024)</date-in-citation></element-citation></ref><ref id="B41-vaccines-12-01452"><label>41.</label><element-citation publication-type="webpage"><article-title>Ponencia de Programa y Registro de Vacunaciones. Consideraciones Sobre Vacunaci&#x000f3;n en el Contexto de la Acogida de Refugiados de Ucrania. Calendario Acelerado para Personas Refugiadas Procedentes de Ucrania</article-title><year>2022</year><comment>Available online: <ext-link xlink:href="https://www.sanidad.gob.es/en/areas/promocionPrevencion/vacunaciones/calendario/calendario/docs/Calendario_Acelerado_Refugiados_Ucrania.pdf" ext-link-type="uri">https://www.sanidad.gob.es/en/areas/promocionPrevencion/vacunaciones/calendario/calendario/docs/Calendario_Acelerado_Refugiados_Ucrania.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-04">(accessed on 4 November 2024)</date-in-citation></element-citation></ref><ref id="B42-vaccines-12-01452"><label>42.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>Consejo Interterritorial del Sistema Nacional de Salud</collab>
</person-group><article-title>2&#x000b0; Estudio de Seroprevalencia en Espa&#x000f1;a. Septiembre 2020</article-title><year>2020</year><comment>Available online: <ext-link xlink:href="https://www.sanidad.gob.es/areas/promocionPrevencion/vacunaciones/comoTrabajamos/docs/EstudioSeroprevalencia_EnfermedadesInmunoprevenibles.pdf" ext-link-type="uri">https://www.sanidad.gob.es/areas/promocionPrevencion/vacunaciones/comoTrabajamos/docs/EstudioSeroprevalencia_EnfermedadesInmunoprevenibles.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-03-17">(accessed on 17 March 2021)</date-in-citation></element-citation></ref><ref id="B43-vaccines-12-01452"><label>43.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group><article-title>Behavioural Sciences for Better Health Initiative. Report by the Director-General. Seventy-Fifth World Health Assembly; Report No.: A75/25</article-title><year>2022</year><comment>Available online: <ext-link xlink:href="https://apps.who.int/gb/ebwha/pdf_files/WHA75/A75_25-en.pdf" ext-link-type="uri">https://apps.who.int/gb/ebwha/pdf_files/WHA75/A75_25-en.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-04">(accessed on 4 November 2024)</date-in-citation></element-citation></ref><ref id="B44-vaccines-12-01452"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hvass</surname><given-names>A.M.F.</given-names></name>
<name><surname>Norredam</surname><given-names>M.</given-names></name>
<name><surname>Sodemann</surname><given-names>M.</given-names></name>
<name><surname>Thomsen</surname><given-names>M.K.</given-names></name>
<name><surname>Christian</surname><given-names>W.</given-names></name>
</person-group><article-title>Are refugees arriving in Denmark an under-immunised group for measles? A cross-sectional serology study</article-title><source>Vaccine</source><year>2020</year><volume>38</volume><fpage>2788</fpage><lpage>2794</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2020.02.025</pub-id><pub-id pub-id-type="pmid">32089459</pub-id>
</element-citation></ref><ref id="B45-vaccines-12-01452"><label>45.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>PAHO</collab>
<collab>WHO</collab>
</person-group><article-title>Immunization Throughout the Life Course in the Americas</article-title><comment>Available online: <ext-link xlink:href="https://paho-cim.shinyapps.io/immunization-dashboard/#" ext-link-type="uri">https://paho-cim.shinyapps.io/immunization-dashboard/#</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-04">(accessed on 4 November 2024)</date-in-citation></element-citation></ref><ref id="B46-vaccines-12-01452"><label>46.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<name><surname>And&#x000e9;rica Fr&#x000ed;as</surname><given-names>G.</given-names></name>
<name><surname>Rivera Cuello</surname><given-names>M.</given-names></name>
<name><surname>del Moral Campa&#x000f1;a</surname><given-names>C.</given-names></name>
<name><surname>L&#x000f3;pez Hern&#x000e1;ndez</surname><given-names>B.</given-names></name>
<name><surname>N&#x000fa;&#x000f1;ez Castillo</surname><given-names>A.</given-names></name>
<name><surname>Garc&#x000ed;a Gestoso</surname><given-names>M.L.</given-names></name>
<name><surname>Jim&#x000e9;nez Al&#x000e9;s</surname><given-names>R.</given-names></name>
<name><surname>Murcia Garc&#x000ed;a</surname><given-names>J.</given-names></name>
<name><surname>Gracias Alfonso</surname><given-names>A.</given-names></name>
<name><surname>Moreno P&#x000e9;rez</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>GU&#x000cd;A Para Examen de Salud Inicial de Menores Extranjeros no Acompa&#x000f1;ados (MENAs); Consejer&#x000ed;a de Salud y Familias; Servicio Andaluz de Salud. June 2019; p. 52</article-title><comment>Available online: <ext-link xlink:href="https://www.juntadeandalucia.es/export/drupaljda/Gu%C3%ADa_MENA2019_DEF_0.pdf" ext-link-type="uri">https://www.juntadeandalucia.es/export/drupaljda/Gu%C3%ADa_MENA2019_DEF_0.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-15">(accessed on 15 November 2024)</date-in-citation></element-citation></ref></ref-list></back><floats-group><fig position="float" id="vaccines-12-01452-f001"><label>Figure 1</label><caption><p>Crude measles incidence rate by birth origin and year. Spain, 2014&#x02013;2022.</p></caption><graphic xlink:href="vaccines-12-01452-g001" position="float"/></fig><fig position="float" id="vaccines-12-01452-f002"><label>Figure 2</label><caption><p>Measles cases born outside Spain, by continent. Spain, 2014&#x02013;2022.</p></caption><graphic xlink:href="vaccines-12-01452-g002" position="float"/></fig><fig position="float" id="vaccines-12-01452-f003"><label>Figure 3</label><caption><p>Kaplan Meier curves for measles cases born outside Spain. 2014&#x02013;2022.</p></caption><graphic xlink:href="vaccines-12-01452-g003" position="float"/></fig><table-wrap position="float" id="vaccines-12-01452-t001"><object-id pub-id-type="pii">vaccines-12-01452-t001_Table 1</object-id><label>Table 1</label><caption><p>Characteristics of measles cases by birth origin. Spain, 2014&#x02013;2022.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">
</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Total</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Born Outside Spain</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Born in Spain</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1"><italic toggle="yes">p</italic>-Value</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">%</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">%</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Cases</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">951</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">177</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">774</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">81.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Sex</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.854</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Male</td><td align="center" valign="middle" rowspan="1" colspan="1">483</td><td align="center" valign="middle" rowspan="1" colspan="1">50.8</td><td align="center" valign="middle" rowspan="1" colspan="1">91</td><td align="center" valign="middle" rowspan="1" colspan="1">51.4</td><td align="center" valign="middle" rowspan="1" colspan="1">392</td><td align="center" valign="middle" rowspan="1" colspan="1">50.6</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Female</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">468</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">49.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">86</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">382</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">49.4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Age group</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">0&#x02013;4 years</td><td align="center" valign="middle" rowspan="1" colspan="1">171</td><td align="center" valign="middle" rowspan="1" colspan="1">18.0</td><td align="center" valign="middle" rowspan="1" colspan="1">20</td><td align="center" valign="middle" rowspan="1" colspan="1">11.3</td><td align="center" valign="middle" rowspan="1" colspan="1">151</td><td align="center" valign="middle" rowspan="1" colspan="1">19.5</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">5&#x02013;29 years</td><td align="center" valign="middle" rowspan="1" colspan="1">307</td><td align="center" valign="middle" rowspan="1" colspan="1">32.3</td><td align="center" valign="middle" rowspan="1" colspan="1">81</td><td align="center" valign="middle" rowspan="1" colspan="1">45.8</td><td align="center" valign="middle" rowspan="1" colspan="1">226</td><td align="center" valign="middle" rowspan="1" colspan="1">29.2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02265;30 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">473</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">49.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">76</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">42.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">397</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">51.3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Imported case</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">89</td><td align="center" valign="middle" rowspan="1" colspan="1">9.4</td><td align="center" valign="middle" rowspan="1" colspan="1">41</td><td align="center" valign="middle" rowspan="1" colspan="1">23.7</td><td align="center" valign="middle" rowspan="1" colspan="1">48</td><td align="center" valign="middle" rowspan="1" colspan="1">6.2</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">862</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">136</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">76.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">726</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">93.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Vaccination status</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.022</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Vaccinated</td><td align="center" valign="middle" rowspan="1" colspan="1">239</td><td align="center" valign="middle" rowspan="1" colspan="1">25.1</td><td align="center" valign="middle" rowspan="1" colspan="1">31</td><td align="center" valign="middle" rowspan="1" colspan="1">17.1</td><td align="center" valign="middle" rowspan="1" colspan="1">208</td><td align="center" valign="middle" rowspan="1" colspan="1">26.6</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Non vaccinated</td><td align="center" valign="middle" rowspan="1" colspan="1">600</td><td align="center" valign="middle" rowspan="1" colspan="1">63.1</td><td align="center" valign="middle" rowspan="1" colspan="1">118</td><td align="center" valign="middle" rowspan="1" colspan="1">67.3</td><td align="center" valign="middle" rowspan="1" colspan="1">482</td><td align="center" valign="middle" rowspan="1" colspan="1">62.8</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unkown status</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">112</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">84</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.6</td></tr></tbody></table></table-wrap><table-wrap position="float" id="vaccines-12-01452-t002"><object-id pub-id-type="pii">vaccines-12-01452-t002_Table 2</object-id><label>Table 2</label><caption><p>Crude measles incidence rates and incidence rate ratios by age group and birth origin. Spain. 2014&#x02013;2022.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Age Group</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Total</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Born Outside Spain</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Born in Spain</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">IRR **</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">CI (95%)</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Measles <break/>Cases (n)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">%</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IR * <break/>(Per Mill)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Measles <break/>Cases (n)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">%</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IR <break/>(Per Mill)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Measles <break/>Cases (n)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">%</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IR <break/>(Per Mill)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>&#x0003c;51</bold>
<break/>
<bold>5 years</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">171</td><td align="center" valign="middle" rowspan="1" colspan="1">18.0</td><td align="center" valign="middle" rowspan="1" colspan="1">9.1</td><td align="center" valign="middle" rowspan="1" colspan="1">20</td><td align="center" valign="middle" rowspan="1" colspan="1">11.7</td><td align="center" valign="middle" rowspan="1" colspan="1">42.3</td><td align="center" valign="middle" rowspan="1" colspan="1">151</td><td align="center" valign="middle" rowspan="1" colspan="1">88.3</td><td align="center" valign="middle" rowspan="1" colspan="1">8.2</td><td align="center" valign="middle" rowspan="1" colspan="1">5.1</td><td align="center" valign="middle" rowspan="1" colspan="1">(3.0&#x02013;8.2)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>5&#x02013;29 years</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">307</td><td align="center" valign="middle" rowspan="1" colspan="1">32.3</td><td align="center" valign="middle" rowspan="1" colspan="1">2.8</td><td align="center" valign="middle" rowspan="1" colspan="1">81</td><td align="center" valign="middle" rowspan="1" colspan="1">26.4</td><td align="center" valign="middle" rowspan="1" colspan="1">5.4</td><td align="center" valign="middle" rowspan="1" colspan="1">226</td><td align="center" valign="middle" rowspan="1" colspan="1">73.6</td><td align="center" valign="middle" rowspan="1" colspan="1">2.4</td><td align="center" valign="middle" rowspan="1" colspan="1">2.2</td><td align="center" valign="middle" rowspan="1" colspan="1">(1.7&#x02013;2.9)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>&#x02265;30 years</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">473</td><td align="center" valign="middle" rowspan="1" colspan="1">49.7</td><td align="center" valign="middle" rowspan="1" colspan="1">1.6</td><td align="center" valign="middle" rowspan="1" colspan="1">76</td><td align="center" valign="middle" rowspan="1" colspan="1">16.1</td><td align="center" valign="middle" rowspan="1" colspan="1">1.8</td><td align="center" valign="middle" rowspan="1" colspan="1">397</td><td align="center" valign="middle" rowspan="1" colspan="1">83.9</td><td align="center" valign="middle" rowspan="1" colspan="1">1.6</td><td align="center" valign="middle" rowspan="1" colspan="1">0.8</td><td align="center" valign="middle" rowspan="1" colspan="1">(0.6&#x02013;1.1)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Total</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">951</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">177</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">774</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">81.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(1.2&#x02013;1.6)</td></tr></tbody></table><table-wrap-foot><fn><p>* IR: incidence rate = measles cases (n)/10<sup>6</sup> inhabitants; ** IRR: incidence rate ratio.</p></fn></table-wrap-foot></table-wrap></floats-group></article>